The objective of the training program in Basic Medical Research in Oncology at the University of Chicago is to provide an outstanding interdisciplinary research training environment for postdoctoral fellows who have completed a minimum of three years of postgraduate training in internal medicine (including at least one year in hematology/Oncology) in order to prepare them for academic careers in oncology. The Section of Hematology/Oncology offers a three-year ACGME training in hematology/oncology with the expectation that candidates for research training will complete one clinical year funded by the hospital and then have a minimum of two or three years of training under the proposed training grant. The direction of the program -- the integration of training in basic and clinical oncology has not changed since the program's inception but we have significantly enhanced our training in clinical research, cancer genomics, population and health services research in response to a national need. Unique structural elements in the training include: 1) access to a diverse population of cancer patients;2) training under the guidance of multidisciplinary research preceptor (s) within project areas;3) specific educational pathways in the form of course work and special seminars leading to a Master of Health Studies degree or Certificate;4) service learning opportunities to reduce cancer disparities and inequities. The research training faculty preceptors interact on a number of collaborative research and training efforts. This interaction is fostered by the close proximity of the investigators at the University of Chicago campus and particularly by their research activities within our NCI-designated comprehensive cancer center. Generally, research programs fall into three distinct areas - patient-oriented research, translational/basic science and population science research. In the proposed training period, we shall continue the successful elements of the program and enhance the curricular offerings by providing coursework in emerging areas of translational research including bioinformatics, cancer genomics, comparative effectiveness, and global health. Our extensive inpatient and outpatient facilities will continue to promote a comprehensive clinical training experience, while our research laboratories will allow for the acquisition of basic science skills. In addition, our diverse population on the southside of Chicago and our Global partners will provide learning opportunities in community based research locally and at International sites. Physicians completing our training program will enter the oncology work force as socially responsible citizens who are prepared for global leadership in oncology and can advance novel interdisciplinary approaches to solve complex problems in cancer research. With the rapid pace of scientific advances and an aging population prone to cancer, a well trained academic oncology work force as proposed in this training program remains a wise investment for the nation.
The objective of the training program in Basic Medical Oncology at the University of Chicago is to provide an outstanding interdisciplinary research training environment for postdoctoral fellows who have completed internal medicine residency training in order to prepare them for academic careers in oncology. Physicians completing our training program will enter the oncology work force as socially responsible citizens who are prepared to advance novel interdisciplinary approaches to complex problems in cancer research and assume global academic leadership in oncology.
|Hensing, Thomas; Chawla, Apoorva; Batra, Rishi et al. (2014) A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol 799:85-117|
|Jain, Nitin; Curran, Emily; Iyengar, Neil M et al. (2014) Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 20:490-8|
|West, Allison H; Godley, Lucy A; Churpek, Jane E (2014) Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 1310:111-8|
|Obeid, Elias; Nanda, Rita; Fu, Yang-Xin et al. (2013) The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 43:5-12|
|Geynisman, Daniel M; Wickersham, Karen E (2013) Adherence to targeted oral anticancer medications. Discov Med 15:231-41|
|Jasielec, Jagoda K; Jakubowiak, Andrzej J (2013) Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol 2:|
|Wheeler, Heather E; Gamazon, Eric R; Wing, Claudia et al. (2013) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19:491-9|
|Locke, Frederick L; Zha, Yuan-yuan; Zheng, Yan et al. (2013) Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol 191:1677-85|
|Lussier, Yves A; Stadler, Walter M; Chen, James L (2012) Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc 19:156-60|
|Njiaju, Uchenna O; Gamazon, Eric R; Gorsic, Lidija K et al. (2012) Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics 22:498-507|
Showing the most recent 10 out of 27 publications